Muhammad Alamgeer

903 total citations
25 papers, 615 citations indexed

About

Muhammad Alamgeer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Muhammad Alamgeer has authored 25 papers receiving a total of 615 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Muhammad Alamgeer's work include Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Muhammad Alamgeer is often cited by papers focused on Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Muhammad Alamgeer collaborates with scholars based in Australia, United States and Singapore. Muhammad Alamgeer's co-authors include Vinod Ganju, D. Neil Watkins, Craig D. Peacock, Vishal Boolell, William Matsui, Beena Kumar, Zdenka Prodanovic, Michal Schneider, Caroline Lum and Daniel J. Gough and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Muhammad Alamgeer

25 papers receiving 606 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Muhammad Alamgeer 346 294 184 176 54 25 615
Qiuhui Li 229 0.7× 221 0.8× 167 0.9× 113 0.6× 31 0.6× 26 508
Andrea Pretta 272 0.8× 182 0.6× 102 0.6× 139 0.8× 44 0.8× 47 478
Juehui Liu 199 0.6× 400 1.4× 178 1.0× 130 0.7× 34 0.6× 11 628
Jay Patrick Lopez 323 0.9× 299 1.0× 66 0.4× 126 0.7× 43 0.8× 20 555
Nikol Snoeren 232 0.7× 203 0.7× 88 0.5× 169 1.0× 39 0.7× 16 522
Catherine J. Kennedy 194 0.6× 234 0.8× 176 1.0× 119 0.7× 22 0.4× 25 560
Kara Penne 256 0.7× 260 0.9× 203 1.1× 154 0.9× 32 0.6× 11 691
Haby Henary 378 1.1× 376 1.3× 199 1.1× 117 0.7× 15 0.3× 32 702
U. Ramp 175 0.5× 435 1.5× 166 0.9× 143 0.8× 50 0.9× 35 629
Tae Sung Ahn 294 0.8× 255 0.9× 119 0.6× 105 0.6× 37 0.7× 45 602

Countries citing papers authored by Muhammad Alamgeer

Since Specialization
Citations

This map shows the geographic impact of Muhammad Alamgeer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muhammad Alamgeer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muhammad Alamgeer more than expected).

Fields of papers citing papers by Muhammad Alamgeer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muhammad Alamgeer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muhammad Alamgeer. The network helps show where Muhammad Alamgeer may publish in the future.

Co-authorship network of co-authors of Muhammad Alamgeer

This figure shows the co-authorship network connecting the top 25 collaborators of Muhammad Alamgeer. A scholar is included among the top collaborators of Muhammad Alamgeer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muhammad Alamgeer. Muhammad Alamgeer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Annette M., Mathias Bressel, Jenny Lee, et al.. (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. The Medical Journal of Australia. 220(2). 80–90. 8 indexed citations
2.
Ling, Ryan Ruiyang, Ryo Ueno, Muhammad Alamgeer, et al.. (2024). FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study). British Journal of Anaesthesia. 132(4). 695–706. 5 indexed citations
3.
Alamgeer, Muhammad, et al.. (2024). Oncology and intensive care doctors' perception of intensive care admission of cancer patients: A cross-sectional national survey. Australian Critical Care. 37(4). 520–529. 2 indexed citations
4.
5.
Tan, Sean, Adam J. Nelson, Muhammad Alamgeer, et al.. (2023). Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study. Heart Lung and Circulation. 33(5). 721–729. 4 indexed citations
6.
Garama, Daniel J., Muhammad Alamgeer, Michael DeVeer, et al.. (2023). MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat. Journal of Experimental & Clinical Cancer Research. 42(1). 100–100. 21 indexed citations
7.
Wang, Yang, et al.. (2023). Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy. JTO Clinical and Research Reports. 4(8). 100544–100544. 2 indexed citations
8.
Alamgeer, Muhammad, Ryan Ruiyang Ling, Ryo Ueno, et al.. (2023). Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study. The Lancet Healthy Longevity. 4(12). e675–e684. 20 indexed citations
9.
10.
Alamgeer, Muhammad, et al.. (2021). P01.22 Outcomes in NSCLC Patients with Early Termination of Immune Checkpoint Inhibitors Due to Toxicities. Journal of Thoracic Oncology. 16(3). S245–S245. 1 indexed citations
11.
Brockwell, Natasha K., Muhammad Alamgeer, Beena Kumar, et al.. (2020). Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. Translational Lung Cancer Research. 9(3). 639–645. 16 indexed citations
12.
Lum, Caroline & Muhammad Alamgeer. (2019). Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer. Cancers. 11(10). 1570–1570. 17 indexed citations
13.
Alamgeer, Muhammad, Peter Briggs, Ben Markman, et al.. (2017). P1.07-004 Updated Analysis of Phase II Study of HA-Irinotecan, a CD44-Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S697–S698. 3 indexed citations
14.
Alamgeer, Muhammad, D. Neil Watkins, Beena Kumar, et al.. (2017). A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer. Investigational New Drugs. 36(2). 288–298. 35 indexed citations
15.
Ng, Sweet Ping, Steven David, Muhammad Alamgeer, & Vinod Ganju. (2015). Impact of Pretreatment Combined 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 93(1). 111–117. 12 indexed citations
16.
Boolell, Vishal, Muhammad Alamgeer, D. Neil Watkins, & Vinod Ganju. (2015). The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers. 7(3). 1815–1846. 96 indexed citations
17.
Alamgeer, Muhammad, Vinod Ganju, Beena Kumar, et al.. (2014). Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research. 16(2). R44–R44. 43 indexed citations
18.
Leong, Tracy L., Kieren D. Marini, Fernando J. Rossello, et al.. (2014). Genomic Characterisation of Small Cell Lung Cancer Patient-Derived Xenografts Generated from Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Specimens. PLoS ONE. 9(9). e106862–e106862. 26 indexed citations
19.
Alamgeer, Muhammad, Vinod Ganju, & D. Neil Watkins. (2013). Novel therapeutic targets in non-small cell lung cancer. Current Opinion in Pharmacology. 13(3). 394–401. 67 indexed citations
20.
Alamgeer, Muhammad, Vinod Ganju, Anette Szczepny, et al.. (2013). The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax. 68(12). 1095–1104. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiuhui Li Breakdown of academic impact, for papers by Andrea Pretta Breakdown of academic impact, for papers by Juehui Liu Breakdown of academic impact, for papers by Jay Patrick Lopez Breakdown of academic impact, for papers by Nikol Snoeren Breakdown of academic impact, for papers by Catherine J. Kennedy Breakdown of academic impact, for papers by Kara Penne Breakdown of academic impact, for papers by Haby Henary Breakdown of academic impact, for papers by U. Ramp Breakdown of academic impact, for papers by Tae Sung Ahn
Rankless by CCL
2026